Lymecycline | CAS#992-21-2 | antibiotic

MedKoo Cat#: 584457 | Name: Lymecycline

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lymecycline is a semisynthetic antibiotic related to TETRACYCLINE.

Chemical Structure

Lymecycline

CAS#992-21-2

Theoretical Analysis

MedKoo Cat#: 584457

Name: Lymecycline

CAS#: 992-21-2

Chemical Formula: C29H38N4O10

Exact Mass: 602.2588

Molecular Weight: 602.64

Elemental Analysis: C, 57.80; H, 6.36; N, 9.30; O, 26.55

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 465.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Lymecycline; Mucomycin; Tetralisal; Limeciclina

IUPAC/Chemical Name

N6-((4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamido)methyl)lysine

InChi Key

AHEVKYYGXVEWNO-RKCBBFCZSA-N

InChi Code

InChI=1S/C29H38N4O10/c1-28(42)13-7-6-9-17(34)18(13)22(35)19-14(28)11-15-21(33(2)3)23(36)20(25(38)29(15,43)24(19)37)26(39)32-12-31-10-5-4-8-16(30)27(40)41/h6-7,9,14-16,21,31,34,36-37,42-43H,4-5,8,10-12,30H2,1-3H3,(H,32,39)(H,40,41)/t14?,15?,16-,21?,28?,29?/m0/s1

SMILES Code

N[C@@H](CCCCNCNC(C(C1=O)=C(O)C(N(C)C)C2CC3C(C)(O)C4=C(C(C3=C(O)C21O)=O)C(O)=CC=C4)=O)C(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Lymecycline is a semisynthetic antibiotic related to TETRACYCLINE.

In vitro activity:

To investigate Lymecycline's ability to reverse acquired EGFR-TKIs resistance, two Icotinib resistant cell lines were constructed. Lymecycline targeted GRB2 and inhibited the resistance of the cell cycle to EGFR-TKI, arresting disease progression and inducing apoptosis in cancer cells. Lymecycline inhibited the resistance of the cell cycle to EGFR-TKI and induced apoptosis in NSCLC by inhibiting EGFR phosphorylation and GRB2-mediated AKT/ERK/STAT3 signaling pathways. Reference: Pharmacol Res. 2020 Sep;159:105007. https://pubmed.ncbi.nlm.nih.gov/32561477/

In vivo activity:

The effect of lymecycline treatment on arthritis in C3H mice produced 5 months previously by i.v. inoculation of Mycoplasma pulmonis was examined. Treatment had little effect on the severity of the clinical disease. However, there was a marked reduction the severity of the histopathological inflammatory reaction in joints from lymecycline-treated mice when compared with untreated controls. Reference: Br J Exp Pathol. 1978 Apr;59(2):204-12. https://pubmed.ncbi.nlm.nih.gov/656320/

Preparing Stock Solutions

The following data is based on the product molecular weight 602.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Chen Y, Wu J, Yan H, Cheng Y, Wang Y, Yang Y, Deng M, Che X, Hou K, Qu X, Zou D, Liu Y, Zhang Y, Hu X. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2. Pharmacol Res. 2020 Sep;159:105007. doi: 10.1016/j.phrs.2020.105007. Epub 2020 Jun 17. PMID: 32561477. 2. Lauhio A, Sorsa T, Lindy O, Suomalainen K, Saari H, Golub LM, Konttinen YT. The anticollagenolytic potential of lymecycline in the long-term treatment of reactive arthritis. Arthritis Rheum. 1992 Feb;35(2):195-8. doi: 10.1002/art.1780350211. PMID: 1310409. 3. Taylor G, Taylor-Robinson D, Keystone EC. Effects of lymecycline on Mycoplasma pulmonis-induced arthritis in mice. Br J Exp Pathol. 1978 Apr;59(2):204-12. PMID: 656320; PMCID: PMC2041341.

In vitro protocol:

In vivo protocol:

1. Taylor G, Taylor-Robinson D, Keystone EC. Effects of lymecycline on Mycoplasma pulmonis-induced arthritis in mice. Br J Exp Pathol. 1978 Apr;59(2):204-12. PMID: 656320; PMCID: PMC2041341.

1: Stanisz BJ, Paszun SK, Zalewska A. Stability of cilazapril in pediatric oral suspensions prepared from commercially available tablet dosage forms. Acta Pol Pharm. 2014 Jul-Aug;71(4):661-6. PubMed PMID: 25272892. 2: Paszun SK, Stanisz BJ, Gradowska A. Cilazapril stability in the presence of hydrochlorothiazide in model mixtures and fixed dose combination. Acta Pol Pharm. 2013 Nov-Dec;70(6):1079-85. PubMed PMID: 24383331. 3: Kolocouri F, Dotsikas Y, Apostolou C, Kousoulos C, Soumelas GS, Loukas YL. Advantages of automation in plasma sample preparation prior to HPLC/MS/MS quantification: application to the determination of cilazapril and cilazaprilat in a bioequivalence study. J AOAC Int. 2011 May-Jun;94(3):758-64. PubMed PMID: 21797003. 4: Łukawski K, Jakubus T, Janowska A, Raszewski G, Czuczwar SJ. Enalapril enhances the anticonvulsant activity of lamotrigine in the test of maximal electroshock. Pharmacol Rep. 2013;65(4):1012-7. PubMed PMID: 24145096. 5: Paszun SK, Stanisz B, Pawłowski W. Rapid and simple stability indicating HPLC method for the determination of cilazapril in pure substance and pharmaceutical formulation in comparison with classic and derivative spectrophotometric methods. Acta Pol Pharm. 2012 Mar-Apr;69(2):193-201. PubMed PMID: 22568033. 6: Narayanam M, Sahu A, Singh S. Use of LC-MS/TOF, LC-MS(n), NMR and LC-NMR in characterization of stress degradation products: Application to cilazapril. J Pharm Biomed Anal. 2015;111:190-203. doi: 10.1016/j.jpba.2015.03.038. Epub 2015 Apr 3. PubMed PMID: 25890215. 7: Kleinbloesem CH, Van Brummelen P, Francis RJ, Wiegand UW. Clinical pharmacology of cilazapril. Am J Med. 1989 Dec 26;87(6B):45S-49S. Review. PubMed PMID: 2532460. 8: Moisejev VS, Ivleva AY, Gurochkin AB, Kobalava ZD. Effects of cilazapril on cardiac structure and function in hypertension. J Cardiovasc Pharmacol. 1994;24 Suppl 3:S70-2. PubMed PMID: 7700070. 9: Karpov YA, Vilchinskaya MY, Sorokin EV, Podinovskaya VA. Efficacy and tolerability of cilazapril in patients with essential hypertension. J Cardiovasc Pharmacol. 1994;24 Suppl 3:S86-8. PubMed PMID: 7700074. 10: Kellaway GS. A comparison of the efficacy of cilazapril versus cilazapril plus hydrochlorothiazide in patients with mild to moderate essential hypertension. Inhibace General Practice Study Group. Eur J Clin Pharmacol. 1993;44(4):377-9. PubMed PMID: 8513849. 11: Dössegger L, Nielsen T, Preston C, Arabatzis N. Heart failure therapy with cilazapril: an overview. J Cardiovasc Pharmacol. 1994;24 Suppl 3:S38-41. Review. PubMed PMID: 7700063. 12: Belz GG, Breithaupt K, Erb K. Review of studies on the clinical pharmacodynamics of cilazapril. J Cardiovasc Pharmacol. 1994;24 Suppl 2:S14-9. PubMed PMID: 7898090. 13: Rosenthal JR, Osowski U. Tolerability and efficacy of antihypertensive treatment with cilazapril in general practice. Cardiology. 1996 Jan-Feb;87(1):54-9. PubMed PMID: 8631045. 14: Krum H, Jackson B, Conway EL, Howes LG, Johnston CI, Louis WJ. Steady-state pharmacokinetics and pharmacodynamics of cilazapril in the presence and absence of cyclopenthiazide. J Cardiovasc Pharmacol. 1992 Sep;20(3):451-7. PubMed PMID: 1279292. 15: Johnston GD, Passmore AP. The effects of cilazapril alone and in combination with frusemide in healthy subjects. Br J Clin Pharmacol. 1989;27 Suppl 2:235S-242S. PubMed PMID: 2527536; PubMed Central PMCID: PMC1379753. 16: Madej A, Gierek-Ciaciura S, Haberka M, Lekston-Madej J, Basiak M, Domańska O, Okopień B. Effects of bisoprolol and cilazapril on the central retinal artery blood flow in patients with essential hypertension--preliminary results. Ups J Med Sci. 2010 Nov;115(4):249-52. doi: 10.3109/03009734.2010.487951. Epub 2010 Sep 22. PubMed PMID: 20858158; PubMed Central PMCID: PMC2971482. 17: Skoczylas A, Adamczak M, Chudek J, Wiecek A. Cilazapril increases plasma ghrelin concentration in obese patients with arterial hypertension. Endokrynol Pol. 2010 Jan-Feb;61(1):21-7. PubMed PMID: 20205100. 18: Stevenson JG, Chideckel EW. Evaluation of cilazapril versus captopril in patients with mild to moderate essential hypertension. Clin Exp Hypertens. 1994 Mar;16(2):179-96. PubMed PMID: 8193609. 19: Kleinbloesem CH, van Brummelen P, Francis RJ, Wiegand UW. Clinical pharmacology of cilazapril. Drugs. 1991;41 Suppl 1:3-10. Review. PubMed PMID: 1712269. 20: Tuncer M, Gunes Y, Guntekin U, Gumrukcuoglu HA, Eryonucu B. Short-term effects of cilazapril and atenolol on P-wave dispersion in patients with hypertension. Adv Ther. 2008 Feb;25(2):99-105. doi: 10.1007/s12325-008-0012-3. PubMed PMID: 18297254.